Price to sales forward of Supernus Pharmaceuticals, Inc. – FWB:S49
This article provides financial information for Supernus Pharmaceuticals, Inc. (S49) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-oriented page from TradingView, lacking detailed analysis but presenting key financial metrics for the company.
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
This article provides a detailed analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting strong near-term sentiment that could lead to a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles with specified entry, target, and stop-loss levels. The analysis also identifies a significant 46.2:1 risk-reward setup, targeting a 13.0% gain against a 0.3% risk.
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This article provides a financial overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), focusing on its forward price-to-book ratio. It presents current market data and notes that the market was closed at the time of publication, indicating no active trades. The content is primarily a data placeholder from TradingView, offering a snapshot of a specific financial metric for the company.
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article displays the Enterprise Value to EBIT forward for Supernus Pharmaceuticals, Inc. (LSE:0LB2) on TradingView. It appears to be a stub or data point rather than a textual analysis, showing the financial metric, period, value, and changes. The page structure includes typical TradingView site navigation and copyright information.
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49)
This article provides an overview of Supernus Pharmaceuticals, Inc. (BX:S49), covering its financial actuals and estimates. It includes analyst price targets, past earnings performance (with a significant positive surprise), revenue figures, and upcoming earnings dates. The article also touches on employee numbers, EBITDA, and how to trade S49 stock.
SUPN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Supernus Pharmaceuticals, Inc. (SUPN) stock, including current price, historical performance, analyst price targets, and key financial metrics. It highlights that analysts estimate a max price of $66.00 and a min price of $55.00, and also covers recent earnings, revenue, and market capitalization. The company's next earnings report is scheduled for August 11, 2026.
S49 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Supernus Pharmaceuticals, Inc. (S49) stock, outlining analysts' price targets, past earnings performance, and future revenue and earnings estimates. It also details financial metrics such as EBITDA, employee count, and confirms that the company does not pay dividends.
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This page provides financial data on Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), specifically focusing on its price-to-earnings forward ratio. The content indicates that the financial metric changes over various periods.
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article provides financial data for Supernus Pharmaceuticals, Inc. (LSE:0LB2), specifically focusing on its Enterprise Value to EBITDA (forward-looking). The content highlights the stock's listing on the London Stock Exchange and is presented within the TradingView platform, offering financial information and market tools for investors.
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U)
This article provides an overview of Supernus Pharmaceuticals, Inc. (A1JX3U) stock, including its current price, analyst forecasts, historical highs and lows, volatility, market capitalization, and financial performance. It highlights that the company's stock is currently trading at 38.8000 EUR with a 2.11% increase, and analysts predict a price range of 46.68 EUR to 56.01 EUR. The report also details recent earnings, revenue, and upcoming earnings release dates, emphasizing that the company does not pay dividends.
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
The article displays the "Price to sales forward" financial metric for Supernus Pharmaceuticals, Inc. (LSE:0LB2) on TradingView. It appears to be a financial data snippet rather than a news article, indicating that no specific value or change could be found within the provided text. The content primarily shows navigation elements and disclaimers for data sources.
Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article focuses on the "Price to earnings forward" metric for Supernus Pharmaceuticals, Inc. (LSE:0LB2) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, indicating that specific value and change data for this metric would be displayed here. The content primarily shows navigation elements and structural information from the TradingView platform rather than a detailed analysis.
Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
The article provides the enterprise value to revenue forward for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and appears to be a financial data point from TradingView. It displays basic company information, stock market data, and navigation for various financial tools and educational resources.
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript
Supernus Pharmaceuticals Inc. reported record total revenues of $719 million in 2025, a 27% increase year-over-year, driven by strong growth in its four key products. Despite this revenue growth and strategic acquisitions like Sage Therapeutics, the company recorded a GAAP net loss of $38.6 million for the full year due to increased expenses and acquisition-related costs. The company also faced supply constraints for its Parkinson's market product, OnapPCO.
Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy
This article analyzes recent insider selling at Supernus Pharmaceuticals, noting that insiders sold US$2.1 million worth of shares over the past year. While some insider selling is normal, the volume at Supernus indicates potential hesitancy among those with intimate knowledge of the company, raising questions for investors.
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
This article analyzes the Q1 performance of several branded pharmaceutical companies, focusing on Supernus Pharmaceuticals (SUPN) and comparing it to peers like Eli Lilly (LLY), Zoetis (ZTS), Corcept (CORT), and Phibro Animal Health (PAHC). It highlights sector trends including advancements in precision medicine and AI adoption as tailwinds, while regulatory scrutiny and patent cliffs act as headwinds. Supernus Pharmaceuticals exceeded revenue expectations but missed EPS estimates, leading to a stock dip, whereas Eli Lilly delivered a strong quarter with significant beats, and Zoetis and Corcept experienced mixed results.
Supernus Pharmaceuticals (SUPN) Stock Could Be 29.4% Undervalued After Strong Quarterly Results
Supernus Pharmaceuticals (SUPN) recently reported strong quarterly results with significant revenue and net profit growth, suggesting the stock may be undervalued by 29.4% according to analyst narratives, with a fair value near $62.83. Despite recent share price fluctuations, the company's strong pipeline, including SPN-820 and SPN-443, supports future growth, though risks include reliance on key products and rising R&D costs. Investors are encouraged to examine the underlying numbers and consider other investment opportunities.
How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors
Supernus Pharmaceuticals recently posted strong quarterly revenue and net profit growth and expanded its partnership with MERGE for digital marketing. This combination of improved financial performance and an enhanced omnichannel marketing strategy for products like Qelbree and its Parkinson's disease brands is expected to influence investor perception of the company's competitive standing in the central nervous system market. The article delves into how these developments, particularly the digital marketing push, may reshape Supernus Pharmaceuticals' investment narrative and its potential impact on future sales and profitability.
Supernus Pharmaceuticals shareholders approve director elections and key proposals
Supernus Pharmaceuticals shareholders approved the election of two Class I directors, the compensation for named executive officers, and the appointment of KPMG LLP as their independent public accounting firm. Additionally, shareholders voted to amend the 2021 Equity Incentive Plan to increase the number of available shares. The company, with a $2.53 billion market cap, saw 16% revenue growth despite a recent loss, and analysts project profitability for the current year.
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan
Supernus Pharmaceuticals, Inc. announced that stockholders approved all four proposals at its 2026 annual meeting. This includes the election of Class I directors Frederick M. Hudson and Charles W. Newhall, III, the non-binding approval of executive compensation, ratification of KPMG LLP as the independent public accounting firm, and an amendment to increase shares under the 2021 Equity Incentive Plan. The outcomes demonstrate strong shareholder support for the company's governance and compensation practices.
Supernus Pharmaceuticals names MERGE as agency of record By Investing.com
Supernus Pharmaceuticals has expanded its seven-year partnership with MERGE, naming it the agency of record for its central nervous system portfolio and digital ecosystem. This expansion follows Supernus's 16% revenue growth, reaching $777 million over the past year, and analysts' forecasts of a return to profitability for the biopharmaceutical company. MERGE will now manage omnichannel marketing for products like QELBREE and Parkinson's disease treatments, alongside digital ecosystem development and sales force support.
Behavioral Patterns of SUPN and Institutional Flows
This article provides an analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details AI-generated trading strategies including position, momentum breakout, and risk hedging, along with specific support and resistance signals across different time horizons. The analysis suggests elevated downside risk in the near term due to a lack of additional long-term support signals.
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals has expanded its partnership with MERGE, naming the latter as its Agency of Record (AOR). MERGE will now lead omnichannel marketing strategy for Supernus' CNS portfolio, including ADHD treatment QELBREE®, and manage Supernus' full digital ecosystem. The expanded agreement aims to leverage MERGE's AI-driven approach to enhance digital engagement and redefine healthcare communication, building on a seven-year relationship.
Supernus Pharmaceuticals Inc (SUPN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Supernus Pharmaceuticals Inc (SUPN), indicating its current valuation score is 9.20. The company ranks 40 out of 157 in the Pharmaceuticals industry, with a P/E ratio of -86.86. Key valuation metrics such as P/B, P/S, and P/CF have not yet been disclosed by the company.
Supernus Pharmaceuticals Inc (SUPN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Supernus Pharmaceuticals Inc (SUPN), detailing its support and resistance levels, indicator values, and moving average status. The current price momentum score is 6.95, and the stock is trading between resistance at $48.66 and support at $41.28. Technical indicators show a mixed signal, with moving averages predominantly indicating a "Sell."
Supernus Pharmaceuticals Inc (SUPN) Earnings Forecast: Future EPS & Revenue Growth Estimates
Supernus Pharmaceuticals Inc (SUPN) has an earnings forecast score of 8.33, ranking 40th in the Pharmaceuticals industry, with an average price target of $61.50 from analysts. The stock's current rating is predominantly "Buy" based on 6 analysts. The expected revenue for the next quarter is $205.29M, and the EPS for the next quarter is projected to be $0.43.
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals has expanded its partnership with MERGE, appointing it as the Agency of Record for its CNS portfolio, which now includes QELBREE® for ADHD, and its entire digital ecosystem. This expanded agreement leverages MERGE's AI-first approach to enhance omnichannel marketing strategies and personalize digital interactions for Supernus' products, including those for Parkinson's disease. The collaboration aims to blend human creativity with AI-driven data and technology to redefine healthcare communication.
Supernus Pharmaceuticals Inc (SUPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Supernus Pharmaceuticals Inc (SUPN), detailing its income by business segments and geographic regions. The company's main revenue drivers are net product sales from Qelbree, GOCOVRI, APOKYN, and Trokendi XR, along with collaboration revenue. The data shows that 100% of its revenue comes from the United States.
Supernus Pharmaceuticals names MERGE as agency of record
Supernus Pharmaceuticals has expanded its seven-year partnership with MERGE, naming it the agency of record for its central nervous system portfolio and digital ecosystem. MERGE will now manage digital marketing and technology platforms for ADHD treatment QELBREE and Parkinson's disease brands APOKYN, GOCOVRI, and ONAPGO, alongside the company's personal promotion efforts. This expansion follows Supernus' 16% revenue growth and analysts' forecasts for a return to profitability this year.
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis
Supernus Pharmaceuticals Inc (SUPN) currently holds a financial score of 7.52, positioning it at 116 out of 157 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 38.63% to $207.71 million and an 80.61% increase in net profit in its latest quarter. While specific detailed financial data points were not disclosed, its overall financial health, operational efficiency, and growth potential scores are notable.
Sage Therapeutics Inc Stock (US78433J1043): Quiet trading as investors await next catalysts after Su
Sage Therapeutics Inc. (SAGE) shares are experiencing quiet trading on Nasdaq in mid-June 2026, following its 2025 acquisition by Supernus Pharmaceuticals. Investors are awaiting new catalysts as no fresh earnings reports or analyst ratings specific to Sage have emerged. The market is primarily focused on the integration of Sage's neuroscience pipeline into Supernus and the combined entity's long-term strategy for brain health disorders.
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
This article recommends avoiding Supernus Pharmaceuticals (SUPN) due to disappointing long-term revenue growth, limited distribution channels as a small company in a regulated industry, and declining return on invested capital (ROIC). Despite a recent stock price drop, analysts do not see a buying opportunity and suggest looking for better investment alternatives. The author provides three reasons for caution with SUPN's stock.
(SUPN) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating weak near and mid-term sentiment but a strong long-term outlook. It presents various AI-generated trading strategies including position trading, momentum, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk due to a lack of additional long-term support signals.
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36
This article reports that Supernus Pharmaceuticals (SUPN) has seen its average price target increased by 32.88% to $59.36. This updated target indicates a positive outlook from analysts regarding the company's future stock performance.
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36
This article reports that the price target for Supernus Pharmaceuticals (SUPN) has been increased by 32.88%, reaching $59.36. No further details are provided regarding the reasons for this adjustment or the analysts involved.
SUPN - Supernus Pharmaceuticals Inc Stock Price and Quote
This article provides a comprehensive overview of Supernus Pharmaceuticals Inc. (SUPN) stock, including its latest trading data, key financial metrics, performance indicators, and recent news. It also includes detailed insider trading information and analyst ratings.
Supernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced its participation in two upcoming investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in a fireside chat at the Jefferies conference, with a live audio webcast available, and investors can arrange meetings with the company at both events. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system (CNS) diseases.
Supernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced its management will participate in two June investor conferences: the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company, focused on CNS diseases, encourages investors to contact conference coordinators for meetings, with a webcast available for the Jefferies event.
How (SUPN) Movements Inform Risk Allocation Models
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) using AI models, identifying neutral near and mid-term sentiment but a positive long-term bias. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also highlights elevated downside risk due to a lack of additional long-term support signals.
Drugmaker Supernus heads to New York and Miami for June investor events
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its participation in two June 2026 investor conferences: the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company will present its financials and business updates, focusing on its therapies for central nervous system diseases. Investors can access a webcast for the Jefferies conference, which will be archived for 60 days.
SUPN PE Ratio & Valuation, Is SUPN Overvalued
Supernus Pharmaceuticals Inc (SUPN) is currently considered undervalued, with a forward PE ratio of 20.16 compared to its five-year average of 20.99. Its fair price is estimated to be between $64.44 and $85.56, making the current price of $48.21 approximately 25.18% undervalued. The company also exhibits a high P/S ratio compared to its competitors, which is deemed sustainable due to robust revenue growth.
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone.
Supernus Pharmaceuticals Inc. will pay Equiniti Trust Company $0.50 per share, totaling approximately $33.4 million, after successfully achieving "Milestone 1" under a contingent value rights agreement. This payment signifies the company's progress in fulfilling its contractual obligations, with funds managed and distributed by Equiniti Trust Company to eligible CVR holders. Such agreements are common in new drug development and M&A, linking future payments to specific milestones.
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone.
Supernus Pharmaceuticals Inc. will pay Equiniti Trust Company $0.50 per share, totaling approximately $33.4 million, after reaching "Milestone 1" under a contingent value rights agreement. This payment signifies the company's progress in fulfilling its contractual obligations, with funds to be distributed to eligible CVR holders by Equiniti. Such agreements are common in drug development and M&A, linking consideration to future performance.
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment
Supernus Pharmaceuticals (NASDAQ: SUPN) is obligated to make a $33.4 million Contingent Value Rights (CVR) milestone payment to eligible holders after achieving "Milestone 1" on March 18, 2026. The company will pay $0.50 per CVR and plans to deposit the funds with the Rights Agent by early June 2026. Despite a recent GAAP net loss in Q1 2026, the company's Q1 revenue surpassed forecasts, and its share price appears undervalued according to InvestingPro analysis, with more cash than debt on its balance sheet.
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone.
Supernus Pharmaceuticals Inc. will pay Equiniti Trust Company $0.50 per share, totaling approximately $33.4 million, after reaching its first milestone under a contingent value rights agreement. This payment reflects the company's successful achievement of contractually stipulated phase results, common in drug development and M&A transactions. Equiniti Trust Company will manage and distribute these funds to eligible CVR holders.
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call Highlights - News and Statistics
Supernus Pharmaceuticals reported strong Q1 2026 results, exceeding revenue and adjusted EBITDA estimates, driven by robust demand for key products like Onepco, Zirzuve, and Kelli. Despite an EPS miss, the company reaffirmed its full-year revenue guidance. The earnings call provided deeper insights into product performance, market penetration strategies, and future M&A considerations.
Trading Systems Reacting to (SUPN) Volatility
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) volatility using AI-generated trading systems. It highlights a neutral sentiment in the near and mid-term but a positive long-term bias, noting that support is being tested. The analysis provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with defined entry points, targets, and stop losses, and identifies an exceptional 43.0:1 risk-reward setup.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced its plan to report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, featuring comments from President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec. Interested parties can access the webcast or pre-register for the dial-in call via the company's investor relations website.
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?
Supernus Pharmaceuticals reported stronger-than-expected Q1 2026 results with increased revenue and a narrower net loss, leading to an 8.9% stock price increase. The company reaffirmed its full-year 2026 outlook, projecting total revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million, indicating management's confidence. While the improved revenue and reaffirmed guidance support the investment narrative, the company's path to consistent profitability still depends on successful execution with its key CNS products to offset rising SG&A and R&D.
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?
Supernus Pharmaceuticals (SUPN) reported stronger-than-expected Q1 2026 results, with revenue of US$207.71 million and a narrowing net loss. The company reaffirmed its full-year 2026 outlook, projecting revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million. This performance and guidance reinforce the investment narrative that Supernus's CNS focus and product pipeline can drive consistent profitability, though profitability challenges remain a near-term risk.
